SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-075722
Filing Date
2024-06-27
Accepted
2024-06-27 16:58:08
Documents
14
Period of Report
2024-06-21
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2418373d1_8k.htm   iXBRL 8-K 34012
  Complete submission text file 0001104659-24-075722.txt   254988

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20240621.xsd EX-101.SCH 3245
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20240621_def.xml EX-101.DEF 26897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20240621_lab.xml EX-101.LAB 36508
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20240621_pre.xml EX-101.PRE 25521
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2418373d1_8k_htm.xml XML 5410
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241080067
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)